{"pmid":32380318,"pmcid":"PMC7198409","title":"Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.","text":["Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.","Autoimmun Rev","Cunningham, Louise","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul","32380318"],"journal":"Autoimmun Rev","authors":["Cunningham, Louise","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380318","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102563","keywords":["covid-19","cytokine storm","il-6","interleukin-6","macrophage activation syndrome","natural killer cells","perforin","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666597097381560320,"score":9.490897,"similar":[{"pmid":32406282,"title":"Tocilizumab: From the Rheumatology Practice to the Fight Against COVID-19, a virus infection with multiple faces.","text":["Tocilizumab: From the Rheumatology Practice to the Fight Against COVID-19, a virus infection with multiple faces.","Expert Opin Biol Ther","Gonzalez-Gay, Miguel A","Mayo, Jose","Castaneda, Santos","Cifrian, Jose M","Hernandez-Rodriguez, Jose","32406282"],"journal":"Expert Opin Biol Ther","authors":["Gonzalez-Gay, Miguel A","Mayo, Jose","Castaneda, Santos","Cifrian, Jose M","Hernandez-Rodriguez, Jose"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406282","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/14712598.2020.1770222","keywords":["covid-19","anakinra","chimeric antigen receptor (car) t cell-induced cytokine release syndrome","colchicine","coronavirus","inflammation","interleukin-6","macrophage activation syndrome","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666802845510270976,"score":95.23774},{"pmid":32350134,"title":"Effective treatment of severe COVID-19 patients with tocilizumab.","text":["Effective treatment of severe COVID-19 patients with tocilizumab.","After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People's Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 +/- 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.","Proc Natl Acad Sci U S A","Xu, Xiaoling","Han, Mingfeng","Li, Tiantian","Sun, Wei","Wang, Dongsheng","Fu, Binqing","Zhou, Yonggang","Zheng, Xiaohu","Yang, Yun","Li, Xiuyong","Zhang, Xiaohua","Pan, Aijun","Wei, Haiming","32350134"],"abstract":["After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People's Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 +/- 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality."],"journal":"Proc Natl Acad Sci U S A","authors":["Xu, Xiaoling","Han, Mingfeng","Li, Tiantian","Sun, Wei","Wang, Dongsheng","Fu, Binqing","Zhou, Yonggang","Zheng, Xiaohu","Yang, Yun","Li, Xiuyong","Zhang, Xiaohua","Pan, Aijun","Wei, Haiming"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350134","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1073/pnas.2005615117","keywords":["covid-19","sars-cov-2","cytokine storm","interleukin-6","tocilizumab"],"link_comment_in":"32278585","e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666138495683395586,"score":77.72242},{"pmid":32474885,"title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","text":["Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists.","Clin Rheumatol","Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet","32474885"],"abstract":["COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists."],"journal":"Clin Rheumatol","authors":["Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474885","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s10067-020-05190-5","keywords":["covid-19","cytokine storm syndrome","hemophagocytic lymphohistiocytosis","macrophage activation syndrome"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668341932687884289,"score":75.43251},{"pmid":32421092,"pmcid":"PMC7224649","title":"SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","text":["SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway.","Cytokine X","Magro, Giuseppe","32421092"],"abstract":["Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway."],"journal":"Cytokine X","authors":["Magro, Giuseppe"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32421092","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cytox.2020.100029","keywords":["baricitinib","covid-19","il-6","il-6 trans-signaling","interleukin-6","ruxolitinib","sars-cov-1","sars-cov-2","sgp130fc","tocilizumab","coronavirus","coronaviruses","drugs","strategies","targets","therapies"],"e_drugs":["INCB018424","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284554661888,"score":74.87353},{"pmid":32422144,"title":"Perforin and resistance to SARS coronavirus 2.","text":["Perforin and resistance to SARS coronavirus 2.","J Allergy Clin Immunol","Cunningham, Louise","Simmonds, Peter","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul","32422144"],"journal":"J Allergy Clin Immunol","authors":["Cunningham, Louise","Simmonds, Peter","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422144","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jaci.2020.05.007","keywords":["bcg","covid","hlh","mas","sars","sars-cov-2","coronavirus","cytokine release","cytokine storm","cytotoxic t lymphocyte","metformin","natural killer","perforin","perforinopathy"],"topics":["Mechanism"],"weight":1,"_version_":1667159284546273280,"score":74.68878}]}